A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
Published on Jun 1, 2011in Cancer Chemotherapy and Pharmacology3.008
· DOI :10.1007/s00280-010-1410-1
Purpose UCN-01 (7-hydroxystaurosporine) is a multi-targeted protein kinase inhibitor that exhibits synergistic activity with DNA-damaging agents in preclinical studies. We conducted a Phase I study to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetic, and pharmacodynamic effects of UCN-01 and irinotecan in patients with resistant solid tumors.